A Blood-Pressure Drug Gives Olaparib a Wider Test

Dartmouth Cancer Center researchers report that telmisartan increased the activity of the PARP inhibitor olaparib in tumors without the homologous-recombination defects that usually predict response. Early human trials are now testing the combination, including in platinum-resistant ovarian cancer. The clinical evidence remains preliminary; the meaningful event is the transition from a repurposing hypothesis into prospective testing.